Private equity firm HIG Capital has agreed to sell its clinical‑research subsidiary, Celerion Holdings, Inc., to the investment firm THL Partners. The deal ends HIG’s ownership of the Lincoln, Nebraska‑based CRO, which it purchased in November 2022. No price has been disclosed, and the transaction is expected to close after customary regulatory approvals.

Founded in 2010, Celerion provides data‑management, biostatistics and clinical‑monitoring services to pharmaceutical and biotechnology clients. Its capabilities help sponsors accelerate trial timelines and ensure data integrity, assets that have become increasingly valuable as drug pipelines expand. HIG’s decision to divest may reflect a strategic shift toward core investments after a brief foray into health services.

The sale transfers ownership of a niche CRO that has built a reputation for rigorous scientific support. For THL Partners, the acquisition adds a platform with established client relationships and a steady revenue stream. With the deal now announced, Celerion will operate under new private‑equity guidance while continuing to serve its pharma partners.

The transaction underscores continued interest from financiers in specialty service providers that support biotech innovation, reflecting a broader trend of private‑equity capital flowing into the drug‑development ecosystem.